

HOW PRESCRIPTION DRUG OUT-OF-POCKET COSTS FOR MEDICARE PART D ARE CHANGING IN 2024, AND WHAT YOU NEED TO KNOW.

The Inflation Reduction Act of 2022 redesigns the Medicare Part D prescription drug benefit design with the goal of **making prescription drugs more affordable and accessible for enrollees.**

THE 4 COVERAGE PHASES OF MEDICARE PART D.

The standard design of the Medicare Part D benefit has 4 distinct phases¹, where patients' prescription OOP costs vary as they move through the coverage phases.



THE INFLATION REDUCTION ACT PROVIDES KEY REFORMS IN 2024 TO PROTECT MEDICARE PART D BENEFICIARIES FROM HIGH OOP COSTS FOR PRESCRIPTION DRUGS.

PART D STANDARD BENEFIT PATIENTS

- **\$0 OOP** costs once they reach the **catastrophic coverage phase**¹
- **Maximum OOP** costs will be **capped at ~\$3300**²



LOW-INCOME SUBSIDY (LIS) PATIENTS*

Expanded eligibility for Part D LIS or *Extra Help* full benefits to patients with limited resources and **income up to 150% of the FPL**¹


FPL=federal poverty level; OOP=out of pocket.

*The LIS program is a federal program that assists in the payment of a portion of Part D prescription drug plan costs such as premiums, deductibles, and copayments.

IMPACT TO MEDICARE PART D STANDARD BENEFIT PATIENTS IN 2024.

In 2024, Part D enrollees who reach the **catastrophic phase** will pay **\$0 out-of-pocket costs for their medications.**³


PHASES OF MEDICARE PART D FOR STANDARD BENEFIT PATIENTS.³



*During catastrophic coverage in 2023, patients receiving standard Part D benefits are responsible for paying 5% of the cost for each of their prescription drugs, or \$10.35 for brand-name drugs (whichever is greater).³

HOW THE LOW-INCOME SUBSIDY (LIS) PROGRAM WILL CHANGE IN 2024.

Financial assistance for prescription drugs will be provided to more Medicare enrollees by increasing the program's income eligibility up to **150% of the FPL**.^{1,†}



~43% of all Medicare Part D patients are projected to have LIS or employer-subsidized coverage, with **reduced OOP costs**⁵

LIS patients have **\$0 deductibles, \$0 premiums**, and will pay no more than **\$11.20** per branded monthly prescription medication such as **ORGOVYX**.^{3,6}

FPL=federal poverty level; OOP=out of pocket.

†In 2024, patients with incomes up to 150% of the FPL, who were previously eligible to participate in the partial LIS program, will be eligible to receive full LIS benefits.

ORGOVYX[®]
(relugolix) 120mg tablets

THE INFLATION REDUCTION ACT WILL MAKE KEY CHANGES TO IMPROVE DRUG AFFORDABILITY FOR PATIENTS WITH MEDICARE PART D COVERAGE IN 2024.

PART D STANDARD BENEFIT PATIENTS



- **\$0 OOP** costs once they reach the catastrophic coverage phase¹
- **Maximum OOP** costs will be **capped at ~\$3300**²

LOW-INCOME SUBSIDY (LIS) PATIENTS



Expanded eligibility for Part D LIS or *Extra Help* full benefits to patients with limited resources and **income up to 150% of the FPL**¹



99% OF MEDICARE PART D PATIENTS
are covered for **ORGOVYX** with **no step therapy**^{7,*}

*This coverage information is provided for informational purposes only; individual plans vary, and this may not include all plans. Sumitomo Pharma America, Inc. and Pfizer make no representation or guarantee concerning coverage or reimbursement; please check with individual payers for plan-specific coverage and reimbursement information and requirements. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced. This information is subject to change without notice.

FPL=federal poverty level; OOP=out of pocket.

The third-party websites listed below are not owned or controlled by Sumitomo Pharma America, Inc. or Pfizer. Sumitomo Pharma America, Inc. and Pfizer make no representations as to the accuracy of the information contained in the sites, and we do not recommend or endorse their content. Use of third-party websites is at your own risk and subject to their terms and conditions of use.

References:

1. Assistant Secretary for Planning and Evaluation. —Inflation Reduction Act research series—Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act. Accessed July 28, 2023. <https://aspe.hhs.gov/sites/default/files/documents/93a68f3c5ca949dcf331aa0ec24dd046/aspe-part-d-oop.pdf>
2. Kaiser Family Foundation. Changes to Medicare Part D in 2024 and 2025 under the Inflation Reduction Act and how enrollees will benefit. Accessed August 30, 2023. <https://www.kff.org/medicare/issue-brief/changes-to-medicare-part-d-in-2024-and-2025-under-the-inflation-reduction-act-and-how-enrollees-will-benefit/>
3. Centers for Medicare & Medicaid Services. Announcement of calendar year (CY) 2024 Medicare Advantage (MA) capitation rates and Part C and Part D payment policies. Accessed August 9, 2023. <https://www.cms.gov/files/document/2024-announcement.pdf>
4. Kaiser Family Foundation. How will the prescription drug provisions in the Inflation Reduction Act affect medicare beneficiaries? Accessed August 10, 2023. <https://www.kff.org/medicare/issue-brief/how-will-the-prescription-drug-provisions-in-the-inflation-reduction-act-affect-medicare-beneficiaries/>
5. Centers for Medicare & Medicaid Services. 2023 annual report of the boards of trustees of the federal hospital insurance and federal supplementary medical insurance trust funds. Accessed August 10, 2023. <https://www.cms.gov/oact/tr/2023>
6. U.S. Department of Health and Human Services. FACT SHEET: Biden-Harris administration announces new tools to lower prescription drug costs for low-income seniors and people with disabilities. Accessed August 30, 2023. <https://www.hhs.gov/about/news/2023/06/12/fact-sheet-biden-harris-administration-announces-new-tools-lower-prescription-drug-costs-low-income-seniors-people-disabilities.html>
7. Data on file. Formulary data provided by MMIT, LLC, as of May 2023. Sumitomo Pharma America, Inc.



◆ is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license.
Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd.
ORGOVYX® and its associated logo are registered trademarks of Sumitomo Pharma Switzerland GmbH.
© 2023 Sumitomo Pharma Switzerland GmbH and Pfizer Inc. All rights reserved. PP-US-REL-2300203 09/23

ORGOVYX
(relugolix) 120 mg
tablets